Impact of Alpha-Ketoglutarate on Skeletal Muscle Health and Exercise Performance: A Narrative Review
Krebs Cycle Cast-Off: The Metabolite That Might Keep Muscle From Melting Away
This is a narrative review, not an experiment. A team from Guangzhou University of Chinese Medicine screened 945 papers on alpha-ketoglutarate (AKG) and kept 112, assembling the case that this ordinary Krebs cycle intermediate acts as a signalling molecule in skeletal muscle rather than merely as fuel. Their argument runs on two tracks. In injury and wasting, animal work suggests AKG expands the muscle satellite cell pool, pushes macrophages from an inflammatory to a repair phenotype, activates the IGF-1/PI3K/Akt/mTOR axis to raise protein synthesis, and suppresses the TNF-alpha/NF-kB arm that drives the MuRF1 ubiquitin ligase and protein breakdown. In exercise, a handful of small human trials report gains in bench press one-rep max and anaerobic peak power. The authors close with dosing suggestions of roughly 2 to 4 grams daily. The evidence base underneath these claims is thinner than the confident framing implies.
Alpha-ketoglutarate has spent most of its scientific life as a bookkeeping entry. It sits in the middle of the Krebs cycle, where isocitrate becomes succinyl-CoA and a molecule of NADH is handed to the electron transport chain. It also serves as the pivot for nitrogen handling, accepting amino groups from amino acids to become glutamate, the parent compound for glutamine, glutathione, GABA and proline. For decades that was the whole story: a metabolic waypoint, not a lever.
The story changing is the reason this review exists. AKG concentrations fall with age. So does the number of muscle satellite cells, the reserve population that repairs damaged fibres. The reviewed animal work suggests these two declines are connected rather than coincidental. Satellite cells taken from aged mice contain less AKG than those from young mice, and adding AKG back restores their capacity to divide. In injured aging mice, intraperitoneal AKG increased both satellite cell number and the cross-sectional area of regenerating fibres, and reduced the fibrous scarring that normally replaces lost muscle.
The wasting side of the argument is broader. AKG blunted muscle loss in mice given corticosterone, in dystrophic mdx mice, in piglets challenged with bacterial endotoxin, and in mice fed a high-fat high-fructose diet. Four different insults, one countermeasure. The proposed common mechanism is that AKG simultaneously raises the protein-building signal through mTOR and lowers the protein-destroying signal carried by NF-kB.
Then the argument thins. The human evidence amounts to a scatter of small trials, most using arginine alpha-ketoglutarate rather than AKG itself, and several pairing AKG with an unrelated compound called 5-hydroxymethylfurfural. Two trials testing the same hypoxia question reached opposite conclusions. Total human participants across the review’s exercise table number in the low hundreds, with several cohorts made up of teenagers.
What the review does well is assemble a plausible mechanistic map. What it does not do is test it. The dosing recommendations in its final section arrive without a dose-response curve to stand on, and the strongest longevity data on AKG, a mouse trial showing compressed morbidity, sits outside the paper’s scope entirely. This is a hypothesis document. Treat it as one.
Actionable Insights
An effect size expresses how large a benefit is relative to the normal spread of results between people. Cohen’s d of 0.2 is small, 0.5 is moderate, 0.8 is large. A d of 0.5 roughly means the average treated person outperforms about 69 percent of untreated people.
The single best human result in this review is Campbell 2006. Thirty-five resistance-trained men took 12 grams per day of arginine-AKG or placebo for eight weeks. Bench press one-rep max rose 8.82 kg in the supplement group versus 2.67 kg on placebo, a 6.15 kg advantage. That converts to a Cohen’s d of about 0.76, moderate to large. Wingate anaerobic peak power ended 129 watts higher, roughly 11 percent, for a d near 0.53. Both confidence intervals nearly touch zero because the trial was small, so the honest read is that the true effect could be anywhere from trivial to substantial.
Three practical caveats matter more than the numbers. First, that trial tested arginine alpha-ketoglutarate, so the arginine may be doing the work. Second, the same trial found nothing for body composition, muscle endurance or aerobic capacity. Third, the review’s suggested doses of 2 to 4 grams per day of plain AKG are not the doses any of the human trials actually used.
Reasonable position: AKG is cheap, well tolerated across the cited trials, and mechanistically interesting for aging muscle. It is not an established intervention. Anyone trialling it should treat it as an experiment with a defined endpoint, not a settled protocol.
Context and Source
Full title: Impact of Alpha-Ketoglutarate on Skeletal Muscle Health and Exercise Performance: A Narrative Review
Institutions: School of Physical Education and Health and South China Research Center for Acupuncture and Moxibustion, Guangzhou University of Chinese Medicine; College of Sports and Health, Guangzhou Sport University. Guangzhou, China.
Journal: Nutrients (MDPI, Basel, Switzerland).
Editorial note: 19 days from submission to acceptance. That is fast for a 112-reference review and is characteristic of MDPI turnaround rather than of unusually deep peer review. [Confidence: High]
Impact evaluation: The impact score of this journal is 5.8 (2025 Journal Impact Factor, Q1, ranked 19 of 114 in Nutrition and Dietetics), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.
You don’t say. And they make poorly supported dosage suggestions. Life is too short to devote any time to reading such. YMMV.